The present invention concerns therapeutic agents that antagonize the activity of glucagon. In accordance with the present invention, the compounds of the invention comprise: a. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the glucagon antagonist domain. The vehicle and the glucagon antagonist domain may be linked through the N- or C-terminus of the glucagon antagonist domain. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

 
Web www.patentalert.com

< Antisense modulation of BH3 interacting domain death agonist expression

< Antisense modulation of syntaxin 4 interacting protein expression

> Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons

> 3',5-difluoro-2',3'-didehydropyrimidine nucleosides and methods of treatment therewith

~ 00097